Aclaris Therapeutics (ACRS) Accumulated Depreciation (2014 - 2025)

Aclaris Therapeutics' Accumulated Depreciation history runs 12 years deep, the most recent figure standing at $5.0 million for Q3 2025.

• In Q3 2025, Accumulated Depreciation rose 6.5% year-over-year to $5.0 million; the TTM figure through Sep 2025 stood at $5.0 million (up 6.5% YoY), while the FY2024 annual figure was $4.8 million, up 15.45% from the prior year.
• Accumulated Depreciation for Q3 2025 stood at $5.0 million, down from $5.0 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $5.0 million in Q2 2025, with the low at $2.9 million in Q1 2021.
• The 5-year median for Accumulated Depreciation is $4.2 million (2023), against an average of $4.1 million.
• The sharpest annual moves came in 2021 and 2024: Accumulated Depreciation gained 29.36% in 2021, then advanced 1.65% in 2024.
• Aclaris Therapeutics' Accumulated Depreciation stood at $3.4 million in 2021, then grew by 18.92% to $4.0 million in 2022, then grew by 3.15% to $4.2 million in 2023, then gained by 15.45% to $4.8 million in 2024, then increased by 3.73% to $5.0 million in 2025.
• Business Quant data shows ACRS's Accumulated Depreciation at $5.0 million in Q3 2025, $5.0 million in Q2 2025, and $4.9 million in Q1 2025.